<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>63</patient-age><report-id>PHHY2012CA005407</report-id><gender>female</gender><reactions><reaction>Excessive bleeding from the intramuscular site on the right side</reaction><reaction>Elevated INR</reaction><reaction>Emotional distress</reaction><reaction>Frustration</reaction><reaction>inflammation due to the several attempts to give the medication</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>SANDOSTATIN LAR</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ANTICOAGULANTS</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Carcinoid tumour of the gastrointestinal tract</indication></indications><outcomes/><country>Canada</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053123_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133626</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>3</safetyreportversion>
		<safetyreportid>PHHY2012CA005407</safetyreportid>
		<primarysourcecountry>CA</primarysourcecountry>
		<occurcountry>CA</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-01-19</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-04</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012CA005407</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportergivename>L</reportergivename>
			<reporterfamilyname>B</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>CA</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>KJ</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19480525</patientbirthdate>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Carcinoid syndrome</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Cardiac operation</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Excessive bleeding from the intramuscular site on the right side</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Injection site bleeding</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Injection site haemorrhage</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Elevated INR</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>INR increased</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>International normalised ratio increased</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Emotional distress</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Emotional distress</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Emotional distress</reactionmeddrapt>
				<reactionstartdateformat>610</reactionstartdateformat>
				<reactionstartdate>201202</reactionstartdate>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Frustration</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Frustration</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Frustration</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>inflammation due to the several attempts to give the medication</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Injection site inflammation</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Injection site inflammation</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<test>
				<testname>International normalised ratio</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>SANDOSTATIN LAR</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationnumb>21-008</drugauthorizationnumb>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>30</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>30 mg, once a month</drugdosagetext>
				<drugdosageform normalized="suspension">Suspension</drugdosageform>
				<drugadministrationroute code="030">Intramuscular</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Carcinoid tumour of the gastrointestinal tract</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-11-22</drugstartdate>
				<actiondrug code="2">Dose Reduced</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>OCTREOTIDE WITH POLY(D L-LACTIDE-CO-GLYCOLIDE)</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Emotional distress</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Emotional distress</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Frustration</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Frustration</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site haemorrhage</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site haemorrhage</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site inflammation</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site inflammation</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>International normalised ratio increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>International normalised ratio increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>SANDOSTATIN LAR</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationnumb>21-008</drugauthorizationnumb>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>40</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>3</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="803">Week</drugintervaldosagedefinition>
				<drugdosagetext>40 mg, TIW (EVERY 3 WEEKS)</drugdosagetext>
				<drugdosageform normalized="suspension">Suspension</drugdosageform>
				<drugadministrationroute code="030">Intramuscular</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-11-22</drugstartdate>
				<actiondrug code="2">Dose Reduced</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>OCTREOTIDE WITH POLY(D L-LACTIDE-CO-GLYCOLIDE)</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Emotional distress</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Emotional distress</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Frustration</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Frustration</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site haemorrhage</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site haemorrhage</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site inflammation</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site inflammation</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>International normalised ratio increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>International normalised ratio increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>SANDOSTATIN LAR</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationnumb>21-008</drugauthorizationnumb>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>30</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>30 mg, every three weeks</drugdosagetext>
				<drugdosageform normalized="suspension">Suspension</drugdosageform>
				<drugadministrationroute code="030">Intramuscular</drugadministrationroute>
				<actiondrug code="2">Dose Reduced</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>OCTREOTIDE WITH POLY(D L-LACTIDE-CO-GLYCOLIDE)</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Emotional distress</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Emotional distress</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Frustration</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Frustration</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site haemorrhage</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site haemorrhage</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site inflammation</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Injection site inflammation</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>International normalised ratio increased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>International normalised ratio increased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>ANTICOAGULANTS</medicinalproduct>
				<obtaindrugcountry>CA</obtaindrugcountry>
				<drugauthorizationcountry>CA</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ANTICOAGULANTS</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012CA005407 is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report from a consumer (patient) via marketing program (Access <Semaphore x="1166624" class="Medicine" value="SandoSTATIN" score="0.97" ID="240093">Sandostatin</Semaphore>) received on 19 Jan 2012 with a follow up report from a <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>received on 23 Mar 2012 with follow up report from the same <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>received on 26 Mar 2012 and another follow up from consumer on 13 Jul 2012 and follow up report received from a <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>via <Semaphore x="1166624" class="Medicine" value="SandoSTATIN" score="0.97" ID="240093">Sandostatin</Semaphore>) Access program on 04 Dec 2012: This report refers to an <Semaphore x="2102861" class="Occupation" value="Legal Occupations" score="1.00" ID="C97637">adult </Semaphore>female patient (patient ID NC0008KH). The patient received <Semaphore x="1166624" class="Medicine" value="SandoSTATIN" score="0.97" ID="240093">Sandostatin </Semaphore><Semaphore x="2123650" class="Procedure" value="Low Anterior Resection" score="1.00" ID="C113716">LAR </Semaphore>(<Semaphore x="941691" class="Medicine" value="Octreotide Acetate" score="0.49" ID="249154">octreotide acetate</Semaphore>) for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of ileocecal <Semaphore x="1676473" class="Disease or Finding" value="Carcinoid Tumor" score="1.00" ID="C2915">carcinoid tumor </Semaphore>from 22 Nov 2011 at a dose of 40 mg per month, and then switched to 40 mg every 3 weeks on an unknown date. The patient reported that she would be receiving the suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore>on 20 Jan 2012 and not on 22 Jan 2012 as she was going to a clinic for an <Semaphore x="2841876" class="MedDRA LLT" value="Cardiac operation" score="1.00" ID="10061026">open <Semaphore x="1725087" class="AnatomicStructure" value="Cardiac Valve" score="1.00" ID="C12729">heart </Semaphore><Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery </Semaphore></Semaphore>that would take <Semaphore x="2440020" class="AnatomicStructure" value="Putamen" score="1.00" ID="C12452">place </Semaphore>on 27 Jan 2012. The patient would have to have 3 <Semaphore x="1724498" class="AnatomicStructure" value="Cardiac Valve Cusp" score="1.00" ID="C33849">valves </Semaphore><Semaphore x="2461946" class="Procedure" value="Replacement Of Lens" score="1.00" ID="C50836">replaced </Semaphore>due to <Semaphore x="1676210" class="Disease or Finding" value="Carcinoid Syndrome" score="1.00" ID="C3215">carcinoid syndrome</Semaphore>. She stated that 2 <Semaphore x="1724498" class="AnatomicStructure" value="Cardiac Valve Cusp" score="1.00" ID="C33849">valves </Semaphore>were to be <Semaphore x="2461946" class="Procedure" value="Replacement Of Lens" score="1.00" ID="C50836">replaced </Semaphore>on the right side (those were the worse ones) and <Semaphore x="1536421" class="AnatomicStructure" value="Aortic Valve" score="1.00" ID="C12670">aortic valve </Semaphore>on the left. The problem was found in Nov 2011. The <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>stated that the patient had <Semaphore x="1907190" class="Disease or Finding" value="Excessive Bleeding" score="1.00" ID="C113742">excessive <Semaphore x="2988829" class="MedDRA LLT" value="Haemorrhage" score="1.00" ID="10055798">bleeding </Semaphore></Semaphore>from the intramuscular site in the left side and the patient also had an elevated <Semaphore x="2064167" class="Procedure" value="International Normalized Ratio of Prothrombin Time" score="1.00" ID="C64805">INR </Semaphore>(<Semaphore x="3045172" class="MedDRA LLT" value="International normalised ratio" score="1.00" ID="10022591">international <Semaphore x="2320043" class="Procedure" value="Normalized Quotient" score="1.00" ID="C54569">normalized </Semaphore>ratio</Semaphore>). Then, the <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>informed that the patient was on <Semaphore x="1608509" class="AnatomicStructure" value="Blood" score="1.00" ID="C12434">blood </Semaphore>thinning medication at this time due to her <Semaphore x="1725087" class="AnatomicStructure" value="Cardiac Valve" score="1.00" ID="C12729">heart </Semaphore><Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery</Semaphore>. On an unspecified date patient <Semaphore x="2433419" class="Procedure" value="Protein Expression Analysis" score="1.00" ID="C63480">expressed </Semaphore>difficulty and <Semaphore x="1948396" class="Disease or Finding" value="Frustration" score="1.00" ID="C61483">frustration </Semaphore>in getting her medication. The patient talked about <Semaphore x="2435694" class="Disease or Finding" value="Psychiatric Disorder" score="1.00" ID="C2893">mental illness</Semaphore>, but when asked, she clarified that she had been experiencing emotional since Feb 2012, when she was hospitalized for a <Semaphore x="1725087" class="AnatomicStructure" value="Cardiac Valve" score="1.00" ID="C12729">cardiac </Semaphore><Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery</Semaphore>. On a not reported date <Semaphore x="1166624" class="Medicine" value="SandoSTATIN" score="0.97" ID="240093">Sandostatin </Semaphore><Semaphore x="2123650" class="Procedure" value="Low Anterior Resection" score="1.00" ID="C113716">LAR </Semaphore>dosage was <Semaphore x="2812482" class="MedDRA LLT" value="Blood magnesium decreased" score="1.00" ID="10005654">reduced to 30 mg </Semaphore>every three weeks. On an <Semaphore x="2665498" class="AnatomicStructure" value="Unspecified Anatomic Sites" score="1.00" ID="C13411">unspecified date<Semaphore x="2057236" class="Disease or Finding" value="Injection Site Arthritis" score="1.00" ID="C27330">, <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680"><Semaphore x="3040617" class="MedDRA LLT" value="Injection" score="1.00" ID="10052995">injection </Semaphore>site </Semaphore></Semaphore></Semaphore>was iced after <Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injections </Semaphore>to decrease <Semaphore x="2055572" class="Disease or Finding" value="Inflammation" score="1.00" ID="C3137">inflammation </Semaphore>due to the <Semaphore x="2199735" class="Race" value="Manzanita" score="1.00" ID="C44529">several </Semaphore>attempts to give the medication. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>and causality of events were not reported.Follow up report from a <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>received on 26 Mar 2012: Added medication details and concomitant medication.Following on internal review on 05 May 2012 of the data received on 26 Mar 2012, following corrections were done: changed from <Semaphore x="1606359" class="Procedure" value="Bleeding Time" score="1.00" ID="C89775">bleeding time </Semaphore>prolongation event to <Semaphore x="3039719" class="MedDRA LLT" value="Injection site haemorrhage" score="1.00" ID="10022067"><Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection site </Semaphore>bleeding </Semaphore>event and upgraded the case.Follow up report received from consumer on 13 Jul 2012: <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">Treatment </Semaphore>dose updated and new <Semaphore x="2724216" class="MedDRA LLT" value="Adverse event" score="1.00" ID="10060933">adverse event </Semaphore>added (<Semaphore x="2927317" class="MedDRA LLT" value="Emotional distress" score="1.00" ID="10049119">emotional <Semaphore x="1860696" class="Disease or Finding" value="Distress" score="1.00" ID="C37942">distress </Semaphore></Semaphore>and <Semaphore x="1948396" class="Disease or Finding" value="Frustration" score="1.00" ID="C61483">frustration</Semaphore>).Follow up report received from a <Semaphore x="1642550" class="Procedure" value="Breast Feels Heavy" score="1.00" ID="C105748">nurse </Semaphore>via <Semaphore x="1166624" class="Medicine" value="SandoSTATIN" score="0.97" ID="240093">Sandostatin</Semaphore>) Access program on 04 Dec 2012: <Semaphore x="2724216" class="MedDRA LLT" value="Adverse event" score="1.00" ID="10060933">Adverse event </Semaphore>(<Semaphore x="2057274" class="AnatomicStructure" value="Injection Site" score="1.00" ID="C77680">injection site </Semaphore><Semaphore x="2055572" class="Disease or Finding" value="Inflammation" score="1.00" ID="C3137">inflammation </Semaphore>due to the <Semaphore x="2199735" class="Race" value="Manzanita" score="1.00" ID="C44529">several </Semaphore>attempts to give the medication) was updated.</narrativeincludeclinical>
				<sendercomment>MR: Concurrent use of anticoagulants was a significant risk factor for the reported event.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>